Even though there were groundbreaking approvals for genetic medicines in sickle cell disease last year, John Evans believes that his start-up can continue to make advancements in the field. Beam Therapeutics began 2024 by announcing that it had administered its base-editing program to the first sickle cell patient, with initial human results expected in the second half of 2024. Endpoints News had the opportunity to discuss Beam’s sickle cell plans amid growing competition, as well as the potential evolution of CRISPR over the next two decades, with Evans, who has been leading Beam since 2017 and was previously an executive at Agios Pharmaceuticals, in a private Slack channel conversation.
